Self-injection device developer Haselmeier, and glass packaging producer Stevanato Group has announced an agreement to license the Axis-D pen-injector technology and intellectual property (IP) for development, manufacturing and supply of the Axis-D pen-injector in diabetes care.
The Axis-D pen-injector was designed and developed by Haselmeier together with its partners, and a version of this pen-injector is currently on the market today having been launched by a major pharmaceutical company and approved for use, among others, by the European Medical Agency (EMA) and the US Food and Drug Administration (FDA). Stevanato Group plans to utilise this technology and IP to provide a new pen injector to support the needs of diabetes patients. Once the design for the device is finalised, it will be produced at one of Stevanato Group’s manufacturing facilities, based on extensive tooling and moulding expertise. Sub-assembly and final assembly equipment will be provided by Stevanato Group operations in Denmark.
Frédéric Gabriel, chief innovation officer at Haselmeier, said: “We are pleased and proud to have Stevanato Group as our strategic partner for Axis-D in Diabetes. Stevanato Group has demonstrated in past years a consistent development strategy coupled with unique integrated capabilities and is able to leverage Haselmeier’s pen injection platform to bring it to the next level. Such platform has already been proven in the market, from an IP, performance and user perspective. It also demonstrates Haselmeier’s strategic orientation to exploit its IP over various paths, either with own development and manufacturing capabilities or together with a strategic partner.”
Paolo Patri, chief technology officer at Stevanato Group, added: “Consistent with its vision Stevanato Group always welcomes strategic agreements with key players in the market to broaden its global capabilities. We value our relationship with Haselmeier as a device technology partner. With this agreement, we continue to expand our portfolio of devices for patients suffering from diabetes. This complements ongoing work on our award winning 1ml cartridge-based wearable device, which will give our biopharmaceutical partners the opportunity to provide patients with both standard and alternative treatment solutions with such devices."
